ABL1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

ASXL1 is altered in 21.67% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains BCR status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

CREBBP is altered in 2.83% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains DEK status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

ETV6 is altered in 4.01% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 9.67% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is altered in 1.18% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [3].

MECOM is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

NPM1 is altered in 4.01% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

PDGFRB is altered in 0.94% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [3].

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain RPN1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [3].

RUNX1 is altered in 22.0% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [3].

TP53 is altered in 27.67% of acute myeloid leukemia with myelodysplasia-related changes patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].